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TNFa drives pulmonary arterial hypertension by
suppressing the BMP type-II receptor and altering
NOTCH signalling
Liam A. Hurst1,*, Benjamin J. Dunmore1,*, Lu Long1, Alexi Crosby1, Rafia Al-Lamki1, John Deighton1,
Mark Southwood2, Xudong Yang1, Marko Z. Nikolic1, Blanca Herrera3, Gareth J. Inman4, John R. Bradley1,
Amer A. Rana1,**, Paul D. Upton1,** & Nicholas W. Morrell1,**
Heterozygous germ-line mutations in the bone morphogenetic protein type-II receptor
(BMPR-II) gene underlie heritable pulmonary arterial hypertension (HPAH). Although
inflammation promotes PAH, the mechanisms by which inflammation and BMPR-II
dysfunction conspire to cause disease remain unknown. Here we identify that tumour
necrosis factor-a (TNFa) selectively reduces BMPR-II transcription and mediates post-
translational BMPR-II cleavage via the sheddases, ADAM10 and ADAM17 in pulmonary
artery smooth muscle cells (PASMCs). TNFa-mediated suppression of BMPR-II subverts
BMP signalling, leading to BMP6-mediated PASMC proliferation via preferential activation
of an ALK2/ACTR-IIA signalling axis. Furthermore, TNFa, via SRC family kinases, increases
pro-proliferative NOTCH2 signalling in HPAH PASMCs with reduced BMPR-II expression. We
confirm this signalling switch in rodent models of PAH and demonstrate that anti-TNFa
immunotherapy reverses disease progression, restoring normal BMP/NOTCH signalling.
Collectively, these findings identify mechanisms by which BMP and TNFa signalling
contribute to disease, and suggest a tractable approach for therapeutic intervention in PAH.
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P
ulmonary arterial hypertension (PAH) is a progressive
disease defined by elevated pulmonary arterial pressure,
often causing death from right heart failure. The pathology
is characterized by increased muscularization and obliteration
of small pulmonary arteries1. Heterozygous germ-line mutations
in the BMPR2 gene, encoding the bone morphogenetic protein
type II receptor (BMPR-II), underlie B70% of heritable (HPAH)
and 20% of idiopathic (IPAH) cases2–4. Most BMPR2 mutations
cause haploinsufficiency and importantly, pulmonary vascular
BMPR-II levels are reduced in non-genetic forms of PAH in
animals and humans5–7.
Despite BMPR2 mutations being the commonest genetic cause
for PAH, the penetrance of mutations in carriers is only 20–30%,
suggesting that additional factors are required for disease
initiation and progression. Inflammation is strongly implicated
as a trigger for disease4,8,9 and promotes the development of PAH
in Bmpr2þ / mice10. Accordingly, PAH patients exhibit
heightened circulating levels of inflammatory cytokines,
including tumour necrosis factor-a (TNFa), that correlate with
poor survival11,12. Of note, transgenic mice overexpressing TNFa
in the lung develop spontaneous PAH13 and lung TNFa
expression is elevated in rats or dogs with pulmonary
hypertension induced with monocrotaline (MCT-PAH) or
a high flow left-to-right shunt14–16. Etanercept, a soluble
TNF-receptor II dimer, prevents and reverses MCT-PAH in
rats17 and reverses PAH in endotoxemic pigs18. Moreover, TNFa
suppresses BMPR-II levels in aortic endothelial cells19. Although
these observations suggest TNFa activity and aberrant BMPR-II
signalling interact in PAH, a direct molecular mechanism
remains elusive.
BMPR-II forms heteromeric cell surface receptor complexes
with activin-like kinase (ALK) type I receptors20, mediating
BMP2, BMP4 and BMP6 signalling with ALK3 in pulmonary
artery smooth muscle cells (PASMCs)21, or mediating endothelial
BMP9/10 responses with ALK1 (refs 22,23). The activated
receptors phosphorylate the canonical Smad1/5/8 proteins20
that promote the transcription of genes including the Inhibitor
of DNA-binding (ID) gene family and NOTCH pathways24,25.
BMPs can also signal independently of Smads, through mitogen
activated protein kinases (MAPKs), and proto-oncogene protein
tyrosine kinase c-SRC (c-SRC) phosphorylation26,27. We have
previously shown reduced BMP4-dependent Smad1/5/8
signalling and transcriptional responses in PASMCs from PAH
patients, especially those harboring BMPR2 mutations28,29.
In contrast to reduced BMP4 signalling, deletion of both
Bmpr2 alleles in mouse PASMCs, or small interfering
RNA (siRNA)-mediated knockdown of BMPR-II protein in
human PASMCs, enhances BMP6 and BMP7-mediated Smad
signalling via recruitment of ACTR-IIA and ALK2 (refs 21,30,31).
Since TNFa reduces endothelial BMPR2 expression19, we
hypothesized that TNFa may critically reduce BMPR2
expression in vascular cells harboring BMPR2 mutations and
switch BMP signalling to recruit ACTR-IIA and ALK2, with
potentially pathological consequences.
Here we demonstrate that TNFa, a key inflammatory mediator,
reduces BMPR2 expression in vascular cells and promotes
ADAM10/17-dependent BMPR-II cleavage in PASMCs, releasing
the soluble ectodomain which acts a ligand trap. Furthermore, we
identify the mechanism by which TNFa, against a background of
BMPR2 genetic loss-of-function, promotes the development of
PAH by driving inappropriate PASMC proliferation through
c-SRC family members and dysregulated NOTCH2/3 signalling.
Moreover, therapeutic etanercept administration reversed
PAH progression in the rat Sugen-hypoxia model and redressed
the NOTCH imbalances. This provides a rationale for the
development of anti-TNF strategies for the treatment of PAH.
Results
TNFa reduces BMPR-II expression in vitro and in vivo. Several
cytokines, including TNFa, IL-1b, IL-6 and IL-8 are implicated
in the pathogenesis of PAH9–13,16. Of these, only TNFa
selectively reduced BMPR2 mRNA and BMPR-II protein
in distal PASMCs (dPASMCs) and pulmonary arterial
endothelial cells (PAECs) (Fig. 1a–d and Supplementary
Fig. 1a–d), via NF-kB p65 (RELA; Supplementary Fig. 1e).
Furthermore, immunofluorescent staining demonstrated local
vascular expression of TNFa in both human IPAH and HPAH
that was absent in unaffected controls (Fig. 1e).
TNFa induces BMPR-II extracellular domain shedding in SMCs.
Unexpectedly, in dPASMCs (Fig. 1c), but not PAECs (Fig. 1d),
the TNFa-mediated reduction of full length BMPR-II levels
(140-150 kDa) was associated with accumulation of an intracel-
lular 60 kDa product (BMPR-II-ICP), confirmed as a BMPR-II
fragment using siRNA (siBMPR2; Supplementary Fig. 2a).
Furthermore, TNFa also promoted the production of this 60 kDa
band and reduction of full length BMPR-II in rat and mouse
PASMCs, human proximal PASMCs (pPASMCs), and human
aortic smooth muscle cells (Supplementary Fig. 2b,c).
To confirm these observations in vivo, we examined BMPR-II
expression in SP-C/Tnf mice13, which overexpress mouse TNFa
in the lung and developed PAH by 8 weeks of age (Fig. 1f and
Supplementary Fig. 3a–c). SP-C/Tnf mice exhibited reduced
Bmpr2mRNA and BMPR-II protein and accumulation of BMPR-
II-ICP in lung, but not liver (Fig. 1g and Supplementary
Fig. 3d,e).
The presence of the BMPR-II-ICP in PASMCs and SP-C/Tnf
lung suggested TNFa-dependent cleavage of BMPR-II. We
confirmed this through immunoprecipitation of a myc-tagged
BMPR-II ectodomain from conditioned media from TNFa-
treated dPASMCs (Supplementary Fig. 4a). Furthermore, ELISA
of conditioned media from TNFa-treated PASMCs revealed
enhanced endogenous soluble BMPR-II (sBMPR-II) generation
(Supplementary Fig. 4b). Since BMPR-II cleavage has not
been reported previously, we determined the proteolytic mechan-
ism of TNFa-mediated cleavage of BMPR-II in PASMCs.
Previous studies demonstrated that matrix metalloproteinase-14
(MMP-14) cleaves the TGFb co-receptors, endoglin and betagly-
can32,33 and A Disintegrin and Metalloprotease-17 (ADAM17)
mediates TGFb type-I receptor ectodomain shedding34.
Accordingly, a pan-MMP/ADAM inhibitor, batimastat (BB94),
inhibited the TNFa-dependent BMPR-II cleavage and sBMPR-II
generation (Supplementary Fig. 4c,d). Transcriptional analysis
of candidate metalloproteinases revealed that TNFa induced
ADAM10 and ADAM17 in dPASMCs, but not PAECs
(Supplementary Fig. 5a,b) and ADAM10 and ADAM17 were
increased in SP-C/Tnf mouse lung homogenates (Supplementary
Fig. 5c). Since ADAM10 and ADAM17 levels do not reflect
altered activity, we examined directly whether either ADAM
was responsible for the BMPR-II cleavage35. Interestingly, only
dual ADAM10/17 inhibition (Supplementary Fig. 5d,e)
or combined siRNAs (Fig. 1h) prevented BMPR-II cleavage
and sBMPR-II generation from PASMCs, confirming that
both ADAM10 and ADAM17 cleave BMPR-II with dual
redundancy.
In silico analysis of published ADAM10/17 cleavage
sites suggested selectivity for alanine-valine (Ala-Val) junctions
and we identified four valines within the transmembrane domain
potentially permitting sBMPR-II generation (Supplementary
Fig. 6a). Mutagenesis of each valine residue demonstrated that
the V163A mutation completely prevented BMPR-II cleavage
(Supplementary Fig. 6b) and sBMPR-II generation (Fig. 1i).
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Many soluble receptor ectodomains function as ligand traps.
Accordingly, commercially sourced recombinant BMPR-II
ECD (Supplementary Fig. 6c), or conditioned media from
TNFa-treated dPASMCs overexpressing wild-type BMPR-II
(Supplementary Fig. 6d), inhibited BMP2 and BMP4 signalling,
whereas media from the cleavage-resistant V163A mutant did
not inhibit these responses (Supplementary Fig. 6d). Of note,
BMPR-II ECD neutralized the anti-proliferative effects of BMP2
and BMP4 (Supplementary Fig. 6e), in a similar manner to
treatment with TNFa (Supplementary Fig. 6f).
TNFa alters BMP signalling and promotes PASMC proliferation.
Having demonstrated that TNFa suppresses BMPR2 expression
in vitro and in vivo, we questioned the impact on BMP signalling
in the context of an existing BMPR2 mutation. We confirmed
that the reduced expression of BMPR2 in dPASMCs from
patients with heritable PAH (HPAH) is further reduced by TNFa
(Fig. 2a and Supplementary Fig. 7a). Previous studies reported
that BMPR-II loss in PASMCs reduces BMP2 and BMP4
signalling, but reveals gain-of-signalling to BMP6 or BMP7
via ALK2 and ACTR-IIA21,30,31. This enhanced BMP7 response
b c
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Figure 1 | TNFa reduces BMPR-II expression and promotes BMPR-II cleavage in PASMCs. (a,b) BMPR2 mRNA expression, normalized to ACTB, in
human dPASMCs (a) and PAECs (b) treated with IL-1b (1 ngml 1), IL-6 (25 ngml 1), IL-8 (25 ngml 1) or TNFa (1 ngml 1) for 24 h (n¼ 3; Student’s
t-test). (c,d) Representative immunoblots of BMPR-II expression in human dPASMCs (c) and PAECs (d) treated with TNFa (1 ngml 1) for 1, 4, 8 or 24 h.
Reprobed for a-tubulin to ensure equal loading. The data shown are representative of three experiments. (e) Representative confocal images of
immunohistochemical staining for TNFa (turquoise) and aSMA (magenta) in lung sections from control, idiopathic and heritable PAH subjects. Nuclei were
counterstained with DAPI (blue). Scale bars, 100 mm. (f) Assessment of right ventricular systolic pressure (RVSP) from Bmpr2þ /þ , SP-C/Tnf/Bmpr2þ /þ ,
Bmpr2þ / and SP-C/Tnf/Bmpr2þ / (n¼4 per group) mice. (g) Representative immunoblots of BMPR-II expression in lungs isolated from 8 week old
Bmpr2þ /þ and SP-C/Tnf/Bmpr2þ /þ transgenic mice. Reprobed for b-actin to ensure equal loading (n¼4). (h) Representative immunoblots of BMPR-II,
ADAM10 and ADAM17 in human dPASMCs transfected with DharmaFECT1 alone (DH1), siADAM10, siADAM17, combined siADAM10þ siADAM17
(siADAM10/17) or non-targeting siRNA control (siCP) with or without TNFa (1 ngml 1) treatment for 24 h. Reprobed for a-tubulin to ensure equal
loading. The data shown are representative of three experiments. (i) ELISA measurement of soluble BMPR-II in conditioned media from human dPASMCs
transfected with wild-type and mutant 50-myc-tagged BMPR-II constructs and treated with TNFa (1 ngml 1) for 24 h (n¼ 3). One-way analysis of variance
with post hoc Tukey’s for multiple comparisons used in f and i. *Pr0.05, ***Pr0.001. Error bars represent mean±s.e.m. Lower molecular mass BMPR-II is
indicated by an arrow.
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was reported to be transient31 and here we confirmed that
siRNA-mediated loss of BMPR-II in control PASMCs led to
an enhanced BMP6-dependent Smad1/5 phosphorylation at 1 h
that was not observed at 4 or 24 h (Supplementary Fig. 7b,c).
As expected, TNFa inhibited BMP2-dependent Smad1/5
phosphorylation and ID1 transcription in control dPASMCs,
but augmented BMP6 signalling, particularly in HPAH PASMCs
(Fig. 2b,c and Supplementary Fig. 7d,e). Functionally, BMP2,
BMP4 and BMP6 inhibited control dPASMC proliferation
whereas BMP6 promoted HPAH dPASMC proliferation
and TNFa enhanced the BMP6 responses (Fig. 2d,e).
The pivotal role of BMPR-II levels in this TNFa/BMP6
response was demonstrated by the switching from anti-
proliferative to pro-proliferative responses following siBMPR2
in control dPASMCs (Fig. 2f), and restoration of the anti-
proliferative response to BMP6 following overexpression of
wild-type BMPR-II in HPAH dPASMCs (Fig. 2g).
In pulmonary vascular cells, BMP2 and BMP6 are relatively
highly expressed (Supplementary Fig. 8a,b). Interestingly, TNFa
repressed BMP2, but consistently induced BMP6 expression in
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Figure 2 | TNFa alters BMP2 and BMP6 signalling dynamics and PASMC proliferation. (a) BMPR2 mRNA expression, normalized to ACTB, in human
dPASMCs from disease-free controls and HPAH patients stimulated with TNFa (1 ngml 1) for 24 h (n¼ 3; Student’s t-test). (b,c) Pre-treatment of human
dPASMCs from disease-free controls and HPAH patients with or without TNFa (1 ngml 1) for 23 h before 1 h stimulation with BMP2 (10 ngml 1) or BMP6
(10 ngml 1). (b) Representative immunoblots of phospho-Smad1/5, total Smad1 and ID1 expression. Reprobed for a-tubulin to ensure equal loading. The
data shown are representative of three control and HPAH cell lines. (c) ID1 mRNA expression, normalized to ACTB (n¼ 3). (d) Proliferation of human
dPASMCs from disease-free controls and HPAH patients after 6 days treatment. Cells treated every 48 h as indicated with BMP2 (10 ngml 1), BMP4
(10 ngml 1) or BMP6 (10, 25 or 50 ngml 1; n¼ 3). (e) Proliferation of human dPASMCs from disease-free controls and HPAH patients after 6 days
treatment. Cells treated every 48 h as indicated with TNFa (1 ngml 1) and/or BMP6 (10 or 50 ngml 1) (n¼ 3 control and HPAH cell lines).
(f) Proliferation of human control dPASMCs on day 6 after transfection with DharmaFECT1 alone (DH1), siBMPR2 or non-targeting siRNA control (siCP)
and treatment every 48 h with TNFa (1 ngml 1) and/or BMP6 (50 ngml 1) as indicated (n¼ 3). (g) Proliferation of human HPAH dPASMCs on
day 6 following transduction with adenovirus expressing full-length wild-type and kinase-dead D485G mutant BMPR-II cDNA and treatment every
48 h with TNFa (1 ngml 1) and/or BMP6 (50ngml 1) as indicated (n¼ 3). One-way analysis of variance with post hoc Tukey’s for multiple comparisons
used in (c–g). *Pr0.05, **Pr0.01, ***Pr0.001. Error bars represent mean±s.e.m.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14079
4 NATURE COMMUNICATIONS | 8:14079 | DOI: 10.1038/ncomms14079 | www.nature.com/naturecommunications
dPASMCs and PAECs (Supplementary Fig. 8c,d), while other
BMP ligands were unaltered (Supplementary Fig. 8e). The BMP2
and BMP6 transcriptional responses were mediated through
NF-kB p65 (RELA) in dPASMCs and PAECS (Supplementary
Fig. 8f,g). Furthermore, BMP6 induction by TNFa was greater in
HPAH dPASMCs than control cells whereas BMP2 expression
was repressed equally (Supplementary Fig. 8h,i). Immunoneu-
tralization using anti-BMP6 or LDN193189, an inhibitor
of ALK2/3/6 (ref. 36) and ACTR-IIA37, in C2C12-BRE cells
reduced the response to TNFa (Supplementary Fig. 9a,b). Also,
LDN193189 inhibited the ID1 response to TNFa in dPASMCs
without affecting the IL8 response, confirming the ID1 response
is indirectly via BMP receptors and not via canonical NF-kB
signalling (Supplementary Fig. 9c,d). Collectively, these
data demonstrate that TNFa reduces BMPR2 and BMP2
expression, but increases BMP6 expression in pulmonary
vascular cells.
To confirm the in vivo relevance of the above, we crossed the
SP-C/Tnf mouse with a Bmpr2þ / mouse that does not develop
significant PAH at baseline38. The highest mean RVSP
was observed in the SP-C/Tnf/Bmpr2þ / mice, although
not significantly different from the mean RVSP measured in
SPC/Tnf/Bmpr2þ /þ mice (Fig. 1f). Right ventricular hyper-
trophy was elevated to similar extents in both genotypes
(Supplementary Fig. 3a), probably due to the high levels of
TNFa expression in this model. However, we observed a greater
repression of Bmpr2 and enhancement of Bmp6 expression in
SP-C/Tnf/Bmpr2þ / mice compared with SPC/Tnf/Bmpr2þ /þ
mice (Supplementary Fig. 3d,f), consistent with our observa-
tions that TNFa may dysregulate BMP signalling on the
background of Bmpr2 haploinsufficiency. Lung TNFa overexpre-
ssion also promoted pulmonary arteriolar muscularization
(Supplementary Fig. 3b,c) and repressed Bmp2 (Supplementary
Fig. 3g), albeit to similar extents in SP-C/Tnf/Bmpr2þ /þ and
SP-C/Tnf/Bmpr2þ / mice.
BMP6 drives HPAH PASMC proliferation via ALK2 and
ACTR-IIA. We next determined the receptors utilized by BMP6
to promote PASMC proliferation. Both LDN193189 (Fig. 3a,b)
and ALK2 siRNA (Fig. 3c,d) abolished the anti-proliferative
response to BMP6 in control PASMCs and the pro-proliferative
response in HPAH PASMCs. Furthermore, ACVR2A siRNA
(siACVR2A) eliminated the enhanced TNFa/BMP6-dependent
Smad1/5 phosphorylation (Fig. 3e), ID1 induction (Fig. 3f)
and proliferative responses (Fig. 3g) of HPAH PASMCs.
TNFa enhanced ACVR2A expression in HPAH PASMCs without
altering ALK2, ALK3 or ALK6 expression (Supplementary
Fig. 10a,b). From these observations, we conclude that
ALK2 mediates BMP6 signalling in PASMCs and TNFa-induced
loss of BMPR-II permits preferential ACTR-IIA signalling,
thus driving HPAH PASMC proliferation.
TNFa alters NOTCH signalling in HPAH PASMCs.
The heightened Smad/ID signalling to BMP6/TNFa is unlikely to
promote dPASMC proliferation since Smad/ID signalling inhibits
PASMC proliferation28,29 and reduced pulmonary vascular
Smad/ID signalling is consistently reported in PAH in humans
and animal models5,39,40. As NOTCH3 is implicated in PASMC
hyperplasia in PAH41,42 and TNFa induces the ADAM17-
dependent cleavage of NOTCH43,44, we examined the expression
levels of the NOTCH family cleaved/transmembrane intracellular
(NTM) regions and NOTCH family mRNA in control
and HPAH dPASMCs. No significant difference was observed
between control and HPAH PASMCs regarding the basal protein
levels of the cleaved/transmembrane intracellular (NTM) regions
of NOTCH1, NOTCH2 and NOTCH3 (Supplementary
Fig. 11a,b). Unexpectedly, TNFa increased the NOTCH1 and
NOTCH2 NTM regions while reducing NOTCH3-NTM, the full-
length NOTCH proteins being too faint to observe (Supple-
mentary Fig. 11c–e). Although NOTCH expression does not
necessarily represent signalling, the transcription of NOTCH2 and
its targets, HEY1 and HEY2 was increased, whereas NOTCH3 and
its target, HES1, were suppressed (Supplementary Fig. 12a–f and
Supplementary Fig. 13a–g), implying NOTCH signalling was
also altered. Since BMP6 enhanced these responses, we
questioned whether BMPR-II and ACTR-IIA regulate NOTCH
expression levels.
In control dPASMCs, siBMPR2 enhanced TNFa-induced
NOTCH2-NTM generation and NOTCH2 transcription, with
little effect on NOTCH1: BMP6 co-incubation accentuated the
NOTCH2 response (Fig. 4a and Supplementary Fig. 14a,b).
BMPR2 silencing also promoted the TNFa-dependent reduction
of NOTCH3-NTM generation and NOTCH3 transcription in the
presence of BMP6 (Fig. 4a and Supplementary Fig. 14c).
In control dPASMCs, the TNFa-dependent NOTCH2 induction
following siBMPR2 was inhibited by co-silencing with siACVR2A
(Supplementary Fig. 14b). Of note, siACVR2A reduced BMP6-
stimulated NOTCH2 expression regardless of siBMPR2 in control
dPASMCs (Supplementary Fig. 14b). In BMPR2 heterozygous
HPAH PASMCs co-treated with TNFa and BMP6, siACVR2A
reduced NOTCH2-NTM generation and abrogated NOTCH3-
NTM reduction (Fig. 4b), whereas TNFa alone had little effect.
The effect on NOTCH1 protein was relatively weak in control
and HPAH cells (Supplementary Fig. 14d,e). Collectively, these
data indicate that TNFa, in particular when added with BMP6,
regulates NOTCH2 and NOTCH3 expression in PASMCs via
preferential ACTR-IIA signalling in BMPR-II-deficient cells.
Consistent with our in vitro data, Notch2 mRNA expression
and NTM levels were increased and Notch3 decreased in the
lungs, but not livers, of mice expressing SP-C/Tnf compared with
control mice (Fig. 4c,d and Supplementary Fig. 14f–h). Moreover,
concentric pulmonary arteriolar lesions in HPAH demonstrated
similar NOTCH2 immunostaining compared with control vessels
(Fig. 4e), but the increased number of PASMCs in the lesion is
consistent with increased total NOTCH2 protein in the
vasculature. In contrast, NOTCH3 levels were low in both
(Fig. 4e).
TNFa/BMP6 drive HPAH PASMC proliferation via NOTCH
signals. We addressed whether NOTCH signalling mediates the
proliferative response of HPAH PASMCs to TNFa/BMP6. The g-
secretase inhibitor, DAPT, previously reported to inhibit PASMC
proliferation through NOTCH3 blockade41, both prevented the
proliferative responses of HPAH PASMCs to TNFa and BMP6
(Supplementary Fig. 15a) and inhibited the anti-proliferative
BMP6 response in control PASMCs (Supplementary Fig. 15b).
NOTCH2 siRNA reduced this proliferation of HPAH PASMCs to
TNFa and BMP6, whereas NOTCH3 siRNA did not (Fig. 4f,g).
In control PASMCs, NOTCH3 siRNA attenuated the anti-
proliferative responses whereas NOTCH2 siRNA had no effect
(Fig. 4h,i). Consistent with the NOTCH2-dependent
proliferation of HPAH dPASMCs to TNFa and BMP6, either
HEY1 or HEY2 knockdown prevented this response
(Supplementary Fig. 15c). Collectively, these data suggest that
in HPAH is associated with loss of the anti-proliferative
NOTCH3 pathway and gain of pro-proliferative NOTCH2
responses via HEY1 and HEY2.
TNFa and BMP6 regulate NOTCH via c-SRC family kinases.
Since the kinase c-SRC integrates BMP and NOTCH signalling
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and has been implicated in PAH27, we questioned whether
the SRC family provided the mechanistic link between
these pathways. SRC family activation was assessed through
tyrosine-527 (Y527) dephosphorylation and tyrosine 416
(Y416) phosphorylation (Fig. 5a). HPAH PASMCs exhibited
SRC family activation to TNFa alone, or with BMP6, whereas
control PASMCs did not (Fig. 5b). Importantly, siBMPR2
transfection in control dPASMCs recapitulated the
SRC activation to TNFa and BMP6 seen in HPAH PASMCs
(Fig. 5c). Conversely, siACVR2A abolished SRC activation
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in HPAH PASMCs (Fig. 5d). Furthermore, the use of two
pan SRC inhibitors in HPAH PASMCs abrogated the
transcriptional induction of NOTCH1 and NOTCH2 and
repression of NOTCH3 by TNFa (Supplementary Fig. 16a–c).
Collectively, these data suggest that TNFa, and to a lesser
extent BMP6, activate SRC kinases to regulate NOTCH1-3 in
PASMCs.
SRC antibodies detect multiple family members, including
FYN and YES, so we determined the contributions of individual
members to the NOTCH responses in HPAH PASMCs
using specific siRNAs (Supplementary Fig. 16d), particularly as
SRC and FYN can interact with BMPR-II27 and ACTR-IIA45,
respectively. In HPAH PASMCs, siRNA targeting FYN prevented
the TNFa-dependent NOTCH1 and NOTCH2 induction
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and NOTCH3 repression (Fig. 5e,f and Supplementary Fig. 16e)
whereas either FYN or YES mediated the repression of NOTCH3
by BMP6 (Fig. 5f). FYN or YES siRNAs also abolished the
proliferative response to TNFa or BMP6 alone, or in combination
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(Fig. 5g). In control PASMCs, loss of YES or SRC reduced
serum-dependent proliferation but minimally impacted on the
BMP6 and TNFa responses (Fig. 5h and Supplementary Fig. 16f).
Anti-TNFa reduces PAH and aberrant TNF/BMP signals
in vivo. Having demonstrated that TNFa subverts
BMP signalling and drives PASMC proliferation via c-SRC and
NOTCH2, we examined this in the rat Sugen-hypoxia (S/H)
model of PAH46 (Supplementary Fig. 17a). We also explored
the impact of the anti-TNFa therapeutic, etanercept (soluble
TNFR-II conjugated to human IgG-Fc) on established PAH.
Exposure of rats to S/H induced robust PAH (Fig. 6a,b)
associated with pulmonary vascular remodelling (Fig. 6c and
Supplementary Fig. 17b). Etanercept reversed the progression of
PAH, reducing RVSP, right ventricular hypertrophy and
muscularization of small alveolar duct-associated arterioles
(Fig. 6a-c), but not the wall thickness of the larger arterioles
associated with terminal bronchioles (Supplementary Fig. 17b),
without altering left ventricular function (Supplementary
Table 1). The development of PAH in the S/H model
was associated with BMP and NOTCH signalling changes
consistent with our in vitro data. Bmpr2 expression and
Smad1/5 signalling were reduced (Fig. 6d,e) and Acvr2a, Alk2,
Bmp6 and Tnf expression were all increased (Fig. 6d and
Supplementary Fig. 17c,d). Also, Notch1, Notch2, Hey1 and Hey2
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expression and medial Notch2 staining were increased in
S/H rats (Fig. 6e,f,h and Supplementary Fig. 17e,f) whereas
Notch3 and Hes1 were reduced (Fig. 6e,g and Suppleme-
ntary Fig. 17g). Furthermore, we observed increased caspase-3
cleavage (endothelial apoptosis) and alpha smooth muscle
actin expression (muscularization; Fig. 6e). In S/H animals
treated with etanercept, the reversal of PAH progression was
associated with restored BMPR-II, phospho-Smad1/5 and Notch3
expression (Fig. 6d,e,g) and a reduction of the pathological
increases in Acvr2a, Alk2, Bmp6, Tnf, Notch2, Hey1, Hey2, cleaved
caspase-3 and alpha-smooth muscle actin (Fig. 6d-f and Supple-
mentary Fig. 17 c,d,f). These observations support our contention
that increased TNFa signalling in PAH causes an imbalance
of BMP and NOTCH signalling that can be redressed through
therapeutic targeting of the TNFa pathway.
Discussion
The mechanisms by which loss-of-function BMPR2 mutations
underlie severe PAH with low penetrance have remained elusive.
Here we provide novel mechanistic insights into a critical
interaction whereby TNFa drives the development of PAH by
repressing vascular BMPR2 transcription and promoting BMPR-
II cleavage in PASMCs. The redundancy between ADAM10
and ADAM17 for BMPR-II cleavage is intriguing. We suggest
that this might permit BMPR-II cleavage only in cells expressing
both ADAMs, restricting this response compared with the
shedding of other molecules by the individual ADAMs.
Ultimately, the impact of severe BMPR-II reduction combined
with enhanced BMP6 signalling via ALK2/ACTR-IIA and c-SRC
family members, promotes PASMC proliferation through
aberrant NOTCH2/3 expression and their downstream transcrip-
tional targets. Furthermore we confirm these alterations in
the hypertensive lungs of PAH patients and preclinical rodent
PAH models. The observation that etanercept treatment in
preclinical PAH normalized BMPR-II levels, restored normal
NOTCH expression levels and reversed the progression of
PAH provides a justification to explore the clinical use of anti-
TNFa approaches in PAH patients.
Inflammatory cytokines are associated with the pathogenesis
of PAH8,9,12 and we demonstrate that local TNFa expression
is present in the medial layers of pulmonary arteries from
IPAH and HPAH patients, but not in control tissues. Given that
we previously reported elevated systemic circulating TNFa levels
of 10.45 pgml 1 in IPAH patients and 9.85 pgml 1 in HPAH
patients compared with 7.92 pgml 1 in controls12, we suggest
that local lung expression is likely to generate appreciably higher
TNFa levels and have a more restricted effect on the pulmonary
circulation than small elevation in these relatively low systemic
levels. Our demonstration that TNFa suppressed BMPR-II
in pulmonary vascular cells confirms reports in osteoblasts47
and aortic endothelial cells19. Furthermore, TNFa exacerbates
the genetic BMPR2 haploinsufficiency in HPAH PASMCs
causing the substantial reduction of BMPR-II levels that allow
BMP6 to switch signalling to the alternative type II receptor,
ACTR-IIA21. Also, TNFa increased BMP6 expression in
PASMCs and hPAECs and induced ACVR2A expression in
HPAH PASMCs. The resulting BMP6/ALK2/ACTR-IIA
utilization induced paradoxical increases in transient Smad1/5
responses, characteristic of BMP receptor complex switching30,31.
Since PAH is associated with reduced Smad signalling39,40, this
transient Smad response was unlikely to promote heightened
PASMC proliferation, so other candidate pathways were
considered.
Emerging evidence implicates NOTCH in the pathogenesis
of PAH. NOTCH inhibition by soluble JAGGED1 attenuates
PAH in hypoxic and MCT-PAH rat models48. Our data
suggest that, on the background of BMPR-II haploinsuffi-
ciency, inappropriate NOTCH2 expression and downstream
HEY1/2 signalling in response to TNFa stimulate PASMC
proliferation. NOTCH2 is abundantly expressed in vascular
SMCs and NOTCH2 deletion reduces SMC number and causes
embryonic lethality49,50. The reduction of NOTCH3 expression
and HES1 signalling we observed was surprising given previous
reports of NOTCH3 promoting PAH41,51,52. However, these
previous studies focussed on NOTCH3 and used DAPT as
the therapeutic intervention in PAH models, which blocks
NOTCH2 and NOTCH3 cleavage. DAPT inhibited the
proliferative responses of our HPAH PASMCs, so NOTCH2
blockade will also be affected in these previous reports.
A previous study demonstrated that NOTCH3 knockout mice
are protected from hypoxia-induced pulmonary hypertension41.
We would contest whether this observation supports a specific
role for NOTCH3 in the development of pulmonary
hypertension, since Notch3 knockout mice demonstrate grossly
abnormal arterial maturation in all vascular beds with altered
myogenic responses and structural defects53. In view of this,
it is not surprising that a mouse deficient in Notch3 during
development exhibits a deficient response to chronic hypoxic
exposure. We observed low baseline NOTCH3 staining in
the pulmonary arterial media, so further reduction in PAH was
not obvious. Although the intensity of NOTCH2 staining
was similar in control and HPAH vessels, proliferation of cells
in the vascular media represented an increase in the number
of NOTCH2-positive cells. Our data imply that NOTCH2,
via HEY1/HEY2, enhances HPAH cell proliferation, while
NOTCH3 appears critical in suppressing PASMC proliferation.
We acknowledge that our data contradicts some aspects
of previous reports regarding the contribution of NOTCH
signalling in PAH, but our studies primarily focus on the
combined impact of TNFa and a background of BMPR2
haploinsufficiency, which is the context relevant to the majority
of human heritable cases.
We explored the role of SRC family kinases in linking the
TNFa, BMP and NOTCH pathways. As BMPR-II sequesters
c-SRC and renders it inactive following BMP stimulation27,
we hypothesized that BMPR-II reduction increases the availability
of SRC kinases to interact with ACTR-IIA or TNFa receptors.
In this context, we identified FYN as a key regulator of the
aberrant NOTCH2 expression and proliferation to TNFa and a
dual role for FYN and YES in the proliferative response to TNFa
and BMP6. To date, only one report has identified an interaction
of FYN and ACTR-IIA in neuronal cells45, so our study is the first
to identify the roles of specific SRC members in the HPAH
PASMC proliferative response, reminiscent of the constitutive
activation of these proto-oncogenes in carcinogenesis54.
In summary, TNFa induces BMP6 and exacerbates the reduced
BMPR-II expression in HPAH PASMCs, enabling BMP6 to
recruit the ALK2/ACTR-IIA receptor complex. TNFa promotes
excessive PASMC proliferation via activation of FYN and the
NOTCH2-HEY1/2 axis, while simultaneously suppressing
the anti-proliferative NOTCH3-HES1 axis. Collectively, these
findings provide a mechanism by which inflammatory TNFa
signalling promotes pulmonary vascular remodelling in the
setting of BMPR-II deficiency in PASMCs. We acknowledge that
TNFa may also impact on endothelial cells to promote
the pathogenesis of PAH. Indeed, we show that TNFa represses
BMPR-II in hPAECs and a previous study reported that TNFa
promotes granulocyte macrophage-colony stimulating factor
(GM-CSF) secretion and macrophage recruitment in BMPR-II-
deficient endothelial cells55. Also, administration of anti-DLL4,
which primarily targets endothelial cell NOTCH1 signalling,
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causes PAH in patients with advanced solid tumours56.
Therefore, the impact of TNFa on endothelial NOTCH
expression and signalling warrants additional investigation.
Such mechanisms may be responsible for disease penetrance
in patients carrying mutations in BMPR-II. Moreover, our
findings justify the testing of anti-TNFa approaches in
treatment of PAH.
Methods
Cell culture and treatments. Human pulmonary artery endothelial cells (PAECs)
were purchased from Lonza (Cat. No. CC-2530; Basel, Switzerland) and
maintained in EGM-2 with 2% FBS (Lonza), as per the supplier’s instructions and
were used between passages 4 and 8. For experimental studies, cells were starved
overnight in Medium 199 containing 0.1% FBS and Antibiotic-Antimycotic
(A/A; 100Uml 1 penicillin, 100mgml 1 streptomycin and 0.25mgml 1
amphotericin B, Invitrogen, Renfrewshire, UK) and incubated in 2% foetal
bovine serum (FBS) containing A/A without growth factors overnight. Cell
lines were routinely tested for mycoplasma contamination and only used
if negative.
Distal human pulmonary artery smooth muscle cells (dPASMCs) were
derived from small vessels (o2mm diameter) lung resection specimens. The
details of the patients from whom the cells were derived are provided in
Supplementary Table 2. The lung parenchyma was dissected away from a
pulmonary arteriole, following the arteriolar tree, to isolate 0.5-to 2-mm-diameter
vessels. These were dissected out and cut into small fragments, which were
plated in T25 flasks and left to adhere for 2 h. A section of the pulmonary
arteriole was collected, fixed in formalin and embedded in paraffin, and
sections were analysed to ensure that the vessel was of pulmonary origin.
Proximal PASMCs were isolated from vessel segments (5-8mm diameter)
that were cut to expose the luminal surface. The endothelium was removed by
gentle scraping with a scalpel blade and the media then peeled away from the
underlying adventitial layer. The medial explants were cut into 4- to 9-mm2
sections, plated into T25 flasks and allowed to adhere for 2 h before addition
of DMEM (Invitrogen) containing 20%(v/v) FBS and A/A (DMEM/20%FBS).
Papworth Hospital ethical review committee approved the use of the human
tissues (Ethics Ref 08-H0304-56þ 5) and informed consent was obtained
from all subjects.
For isolation of peripheral lung rat PASMCs, rats were anaesthetized with
pentobarbitone sodium (Sagatal, 60mg kg 1 i.p.), a small incision made in the
neck and the trachea cannulated. The chest was opened and the pulmonary
artery cannulated with a metal cannula introduced through the right ventricle.
An incision was made in the left atrium the lungs rinsed via the pulmonary
artery catheter using warm PBS (10ml) with Heparin (500Uml 1). Prewarmed
(37 C) 0.5% Ferric oxide (Fe3O4, cat.no. 310069, Sigma-Aldrich, Gillingham,
Dorset, UK)/1% agarose in DMEM was slowly injected via the PA cannula followed
by injection of 1% agarose in DMEM via the tracheal cannula. The lung block
was excised and transferred to DMEM on ice for about 20min to set the agarose.
The lungs were sliced with subsequent trimming of the subpleural margin to a
depth of no more than 1mm and the slices minced with a razor blade and partially
digested with type II collagenase (80Uml 1 of culture medium) for 30min at
37 C. The tissue was sheared through 18 gauge needles, transferred to 12 75-mm
glass tubes, placed in a magnetic separator (Promega, Madison, WI) and rinsed
with DMEM (4 C) until a clear discard solution was obtained. The microvessels
were isolated magnetically, resuspended in 1ml of DMEM/20%FBS, plated
in a 25 cm2 tissue culture flask, and incubated in humidified air with 5% CO2 at
37 C. On day 2, an additional 4ml of DMEM/20%FBS was added to each flask.
Once confluent, the cells were detached with trypsin (0.05%) and 0.02% EDTA
in Hanks’ balanced salts (HBSS) and cultured in DMEM/20%FBS. Mouse
PASMCs were isolated from explants of small pulmonary arteries (0.5mm internal
diameter) microdissected from wild-type mice.
Once adhered, tissue explants were incubated in DMEM/20% FBS until
cells had grown out and were forming confluent monolayers. PASMCs were
trypsinized, and subsequent passages were propagated in DMEM supplemented
with 10% heat-inactivated FBS and A/A (DMEM/10% FBS) and maintained at
37 C in 95% air-5% CO2. The smooth muscle phenotype was confirmed by
positive immunofluorescent staining using an antibody to smooth muscle specific
alpha-actin (Clone IA4 Sigma-Aldrich; 1:100 dilution). Human aortic smooth
muscle cells isolated from patients providing informed written consent, under
local ethics approval (NRES Committee East of England – Norfolk). Aortic cells
were kindly provided by Dr Murray Clarke (University of Cambridge, UK). All
smooth muscle cell lines were used between passages 4 and 8.
C2C12-BRE cells, a subcloned population of C2C12 myoblasts stably expressing
Smad-responsive BMP response element (BRE) generated in the laboratory of
Dr G.Inman, were cultured in DMEM (10% FBS, 2mM L-glutamine and
700mgml 1 G418)57.
Smooth muscle cells and C2C12-BRE cells were quiesced in DMEM containing
0.1% FBS and A/A overnight before treatments. Recombinant human TNFa,
BMP2, BMP4, BMP6, IL-1b, IL-6 and IL-8 were purchased from R&D Systems
(Oxfordshire, UK). Recombinant mouse TNFa was purchased from PeproTech
(Rocky Hill, NJ). Cells were treated with TNFa (1 ngml 1) for 24 h,
unless otherwise indicated. Cells were stimulated with BMP2, BMP4 or
BMP6 (10 ngml 1 unless otherwise stated) or co-stimulated with TNFa and
BMP ligand as indicated. The metalloprotease inhibitor batimastat (BB94)
(10 ngml 1) was a kind gift from Dr. Murray Clarke (University of Cambridge,
UK). ADAM10 inhibitor GI254023X (10 mM) was a kind gift from Prof. Andreas
Ludwig (RWTH AACHEN, Germany)58. The anti-ADAM17 antibody, D1(A12)
(50 nM) was a kind gift from Prof Gillian Murphy (Cancer Research UK Research
Institute, Cambridge, UK)59. ADAM10/17 inhibitor TAPI-1 (10 mM) was
purchased from Enzo Life Sciences (Devon, UK). The BMP signalling inhibitor,
LDN193189, was a kind gift from Dr. Paul Yu (Brigham and Women’s Hospital,
Boston, MA). The g-secretase inhibitor, DAPT, was from Sigma-Aldrich. Unless
otherwise stated, cells were pretreated with inhibitors for 30min before TNFa
stimulation and then added to cells for a total of 24 h. For immunoneutralization
studies, treatments were preincubated with 1 mgml 1 monoclonal anti-BMP2
(MAB3551, R&D Systems) or anti-BMP6 (MAB507, R&D Systems) for 1 h
before adding to cells.
Cell proliferation. For assessment of PASMC proliferation, cells were seeded at
15,000 cells per well in 24-well plates and left to adhere overnight. After 48 h, cells
were washed with DMEM containing 0.1% FBS and A/A and then serum-restricted
in DMEM containing 0.1% FBS and A/A for 16 h. Cells were then exposed to the
stated treatments in DMEM containing 5% FBS and A/A and treatments were
replenished every 48 h. At the relevant time points, cells were trypsinized and
counted on a hemocytometer using trypan blue exclusion to assess cell viability.
Expression plasmids and reagents. The pcDNA3 expression plasmid
encoding 50-myc-tagged BMPR-II wild type was prepared as previously
described60. Mutant myc-tagged BMPR-II V158A, V160A, V163A and V166A
plasmids were created using the QuikChange Site-Directed Mutagenesis kit
(Agilent Technologies, Cheshire, UK) according to the manufacturer’s instructions
(Supplementary Table 3). The presence of each mutation was verified by
sequencing.
Adenoviral transduction. The replication incompetent serotype
5 adenoviral plasma vectors, AdCMVBMPR2myc61 and kinase-dead
AdCMVBMPR2(D485G)myc61, were digested with Pac1 and transfected
into HEK293T cells. Large-scale virus preps were generated in HEK293 cells and
purified by cesium chloride centrifugation. Viral titer was determined by
TCID50 assay and particle titer by OD260. Cells were infected with 50 plaque-
forming units (pfu) per cell for 4 h in serum-free DMEM and this was then
replaced with DMEM/10% FBS for 16 h. Before treatment cells were
serum-restricted in DMEM containing 0.1% FBS and A/A for 16 h and then treated
with ligands in DMEM containing 5% FBS and A/A, with replenishment of
ligands every 48 h. Cells were trypsinized and counted on day 6.
Plasmid transfections. Plasmids were prepared using the PureLink maxiprep kit
(Invitrogen), according to the manufacturer’s instructions. Before transfection,
PASMCs were incubated with Opti-MEM-I (Invitrogen) for 2 h. Cells were
transiently transfected with 4 mg of expression plasmid using 2 ml Lipofectamine
2000 reagent (Invitrogen) in Opti-MEM-I. Cells were incubated with transfection
mixes for 4 h, followed by replacement with DMEM/10% FBS for 48 h before
quiescence and treatment as indicated. Transfection efficiency was confirmed via
BMPR-II and Myc tag immunoblotting.
siRNA transfections. Before transfection, PASMCs were incubated with
Opti-MEM-I serum-free medium (Invitrogen) for 3 h before adding 10 nM siRNA
lipoplexed with DharmaFECT1 (GE Dharmacon, Lafayette, CO) siRNA/Dhar-
maFECT1 complexes were allowed to form for 20min at room temperature
before being added to the cells. Cells were then incubated with the complexes
for 4 h at 37 C before returning to DMEM/10% FBS overnight. Knockdown
efficiency was confirmed by immunoblotting or mRNA expression. The siRNAs
used were: ON-TARGETPlus Smartpool oligos for (4x% values represent
knockdown at RNA level): ACVR2A (473%), ADAM10, ADAM17, ALK2
(484%), BMPR2 (475%), RELA (482%, encoding NF-kB p65) or a
non-targeting control pool (siCP) (all GE Dharmacon) or oligos targeting
FYN (464%, SASI_Hs01_00195124), HEY1 (463%, SASI_Hs01_0052320),
HEY2 (463%, SASI_Hs02_00343977), NOTCH2 (450%, SASI_Hs01_00068801),
NOTCH3 (475%, SASI_Hs01_00101287), SRC (462%, SASI_Hs01_00112907)
or YES (468%, SASI_Hs01_00086922) from Sigma-Aldrich. For proliferation
experiments, we confirmed that the level of knockdown was similar at days 2, 4 and
6 for each target.
Immunoblotting. Frozen liver and lung tissue were homogenized in lysis buffer
(250mM Tris-HCl, pH 6.8, 4% SDS, 20% v/v glycerol, EDTA-free protease
inhibitor cocktail (Roche, West Sussex, UK)) sonicated and centrifuged for
15min at 15,000g. PAECs and PASMCs were snap-frozen on an ethanol-dry ice
bath in lysis buffer (125mM Tris (pH 7.4), 2% SDS, 10% glycerol, and EDTA-free
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protease inhibitor cocktail). Cell lysates (20–100 mg protein) were separated by
SDS-PAGE and proteins transferred to polyvinylidene fluoride membranes by
semidry blotting (GE Healthcare, Buckinghamshire, UK). Membranes were then
blocked and probed with rabbit polyclonal antibodies toward total Smad1 (cat.
#9743; 1:1,000 dilution), phosphorylated SRC(Y527) (cat. #2105; 1:1,000 dilution)
(all Cell Signaling Technology, Danvers, MA), ADAM10 (cat.no. ab1997;
1:1,000 dilution), ADAM17 (cat.no. ab39162; 1:1,000 dilution) Abcam,
Cambridgeshire, UK); rabbit monoclonal antibodies toward phosphorylated
Smad1/5 (cat. #9516; clone 41D10; 1:1,000 dilution), caspase-3 (cat. #9665;
clone 8G10; 1:1,000 dilution), cleaved caspase-3 (cat. #9664; clone 5A1E; 1:1,000
dilution), NOTCH1 (cat. #3608; clone D1E11; 1:1,000 dilution), NOTCH2
(cat. #5732; clone D76A6; 1:1,000 dilution), NOTCH3 (cat. #5276; clone D11B8;
1:1,000 dilution), phospho-SRC(Y416) (cat. #6943; clone D49G4; 1:1,000 dilution),
SRC (cat. #2123; clone 32G6, all Cell Signaling Technology, Danvers, MA),
ID1 (cat.no. M085; clone 195-14, CalBioreagents, San Mateo, CA; 1:1,000 dilution);
or mouse monoclonal antibodies towards BMPR-II (cat.no. BD612292;
clone 18/BMPR-II, BD Transduction Laboratories, Franklin Lakes, NJ; 1:250 for
SMCs and 1:400 for PAECs), c-Myc (cat.no. sc40; clone 9E10, Santa Cruz
Biotechnology, Dallas, TX; 1:1,000 dilution). After washing, blots were incubated
with secondary anti-mouse horseradish peroxidase (HRP) antibody (cat.no. P0447;
Dako, Cambridgeshire, UK; 1:2,000 dilution) or anti-rabbit horseradish peroxidase
antibody (cat.no. P0448; Dako; 1:2,000 dilution) for 1 h at room temperature.
As a loading control, all blots were re-probed with a mouse monoclonal antibody
toward either a-tubulin (T6199; clone DM1A, Sigma-Aldrich; 1:5,000 dilution
and 1:5,000 anti-mouse HRP) or b-actin (A5441; clone AC-15, Sigma-Aldrich;
1:7,500 dilution and 1:7,500 anti-mouse HRP). Densitometry was performed
using ImageJ software. Membranes were developed using enhanced chemilumi-
nescence (GE Healthcare). Uncropped western blots are presented in
Supplementary Figs 18–39.
Deglycosylation. Protein was deglycosylated using PNGase F according to the
manufacturer’s instructions (New England Biolabs, Hitchin, Hertfordshire, UK).
Approximately 60–80 mg of protein was deglycosylated and then fractionated
by SDS–PAGE.
Immunoprecipitation. Conditioned media were taken from transfected PASMCs
before lysis. Media were centrifuged at 2,000g (4 C) to remove cellular debris and
stored in 1ml aliquots at  80 C. For immunoprecipitation, 1ml culture media
were incubated with a mouse monoclonal toward BMPR-II (cat.no. MAB811;
Clone # 73805, R&D Systems; final dilution¼ 8 mgml 1) overnight on a rotary
mixer at 4 C. Antibody:protein complexes were isolated by incubation with
protein-G sepharose beads (Sigma-Aldrich) for 4 h on a rotary mixer at 4 C. Beads
were washed three times in PBS/Triton X-100 (0.1%; Sigma-Aldrich) and
resuspended in 2 loading buffer containing 62.5mm Tris–HCL, pH 6.8,
10% (v/v) glycerol, 2% (w/v) SDS, 5% (v/v) b-mercaptoethanol, 0.003% (w/v)
bromophenol blue. To detach complexes from the beads, samples were boiled
at 99 C for 5min and centrifuged at 2,500g for 2min at 4 C. Samples were
separated by SDS-PAGE and immunoblotted for myc tag as previously described.
sBMPR-II ELISA. Conditioned media, taken from PASMCs stimulated with TNFa,
were centrifuged at 2,000 g (4 C) to remove cellular debris and stored in 1ml
aliquots at  80 C. BMPR-II ECD was measured using an in-house ELISA. ELISA
was performed as previously described with the following modifications62. Briefly,
flat-bottom high binding 96-well ELISA plates (Greiner, South Lanarkshire, UK)
were coated with 1 mgml 1 mouse monoclonal anti-human BMPR-II antibody
(R&D Systems) for 2 h at room temperature. After washing, plates were blocked
with 1% BSA (Sigma-Aldrich) in PBS-T for 1 h at room temperature. Aliquots
of standards (His-tagged BMPR-II-ECD, Sino Biologicals, Beijing, China) and
conditioned media with the relevant controls were added and incubated
in a humidified chamber overnight at 4 C. After washes, polyclonal rabbit
anti-human BMPR-II antibody (Santa Cruz Biotechnology), diluted to 0.5 mgml 1
in 1% BSA/PBS-T, was added and incubated for 3 h at room temperature.
Plates were washed as described and goat anti-rabbit alkaline phosphatase
conjugate whole molecule IgG (Sigma-Aldrich) was added at a 1:1,000 dilution in
1% BSA/PBS-T, and incubated for a further 2 h at room temperature. Plates
were developed and read at 405 nm in an automated plate reader (3550, Bio-Rad).
Results were analysed using Microplate Manager software (Bio-Rad, Hemel
Hempstead, Hertfordshire, UK). The lower level sensitivity of this assay
was 750 pgml 1.
sBMPR-II ligand-binding assay. C2C12-BRE cells were treated with BMP2 or
BMP4 (at 1 and 10 ngml 1) in the presence or absence of commercially available
glycosylated His-tagged BMPR-II-ECD (Sino Biologicals) or conditioned media
from transfected PASMCs stimulated with TNFa. Luciferase activity in the cells
was assessed using a luciferase reporter assay kit (Roche).
RNA preparation and quantitative reverse transcription–PCR. Total RNA
was extracted using the RNeasy Mini Kit with DNAse digestion (Qiagen, West
Sussex, UK). cDNA was prepared from B1 mg of RNA using the High Capacity
Reverse Transcriptase kit (Applied Biosystems, Foster City, CA), according to
the manufacturer’s instructions. All quantitative PCR reactions were prepared in
MicroAmp optical 96-well reaction plates (Applied Biosystems) using 50 ng ml 1
cDNA with SYBR Green Jumpstart Taq Readymix (Sigma-Aldrich), ROX reference
dye (Invitrogen) and custom sense and anti-sense primers (all 200 nM). Primers
for human: ACTB (encoding b-actin), ADAM10, ADAM12, ADAM15,
ADAM17, ALK3, BMPR2, HES1, HEY1, HEY2, ID1, MMP14, MMP15,
MMP16, MMP17, MMP24, NOTCH3; mouse Acvr2a (encoding Actr-IIa), Alk2,
Bmpr2, Notch1, Notch2 and Notch3 were all designed using Primer3
(http://primer3.sourceforge.net/) (Supplementary Tables 4–6). QuantiTect primer
assays (Qiagen) for: human ACVR2A (encoding ACTR-IIA), ALK2, ALK3, ALK6,
BMP2, BMP4, BMP6, BMP7, BMP9, IL8, NOTCH1, NOTCH2; mouse Bmp2, Bmp6;
and rat Bmpr2, Notch1, Notch2, Notch3 and Tnf Reactions were amplified on
a StepOnePlus Real-Time PCR system (Applied Biosystems).
Relative expression of each target gene was identified using the comparative
2-(DDCt) method. Target gene expression was normalized to ACTB and the
difference in the amount of product produced was expressed as a fold change.
The relative abundance of BMP ligands was calculated, on the assumption of
equal copy number, by calculating the expression of each BMP gene relative to
ACTB after normalization to B2M.
Rodent models of PAH. Group numbers were determined using estimates of
variance and minimum detectable differences based on our previous experience
with rodent models of PAH. Randomized of animals, using an assigned animal
identification number, allowed investigators performing cardiopulmonary
measurements to be blinded to genotype or treatment group. Animal studies
was conducted in accordance with the UK Animals (Scientific Procedures)
Act 1986 and approved under Home Office Project License 80/2460.
SP-C/Tnf mouse model. Sperm from transgenic SP-C/TNF-a mice
(expressing a mouse Tnf cDNA driven by the human Surfactant Protein-C
promoter) bred on a C56/Bl6 background was kindly provided by Associate Pro-
fessor Masaki Fujita (Fukuoka University, Japan)13. Mice were generated through
in vitro fertilization and bred through 2 generations of C57/Bl6 Jax before crossing
male SP-C/Tnf mice with female Bmpr2þ / mice on an established C57/Bl6
Jax background. Offspring were aged to 8–9 weeks and then assessed for
pulmonary haemodynamics (Wild-type¼ 4 females; SP-C/Tnf¼ 4 females;
Bmpr2þ / ¼ 3 males, 1 female, SP-C/Tnf x Bmpr2þ / ¼ 3 males, 1 female).
Mice were anesthetized with 0.5mg kg 1 fentanyl and 25mg kg 1 fluanisone
(Hypnorm, VetaPharma Ltd, Leeds, UK) and 12.5mg kg 1 midazolam
(Hypnovel), and right ventricular pressures and volumes were recorded using a
Millar SPR-139 catheter (Millar Instruments, Houston, TX). Mice were then
sacrificed and the hearts, lungs and livers were harvested. Right ventricular
hypertrophy (RVH) was assessed by removing the heart and dissecting the
right ventricle (RV) free wall from the left ventricle plus septum (LVþ S) and
weighing separately. The degree of right ventricular hypertrophy was determined
from the ratio of RV/LVþ S (Fulton Index). The right lung was snap frozen in
liquid nitrogen. The left lung was inflated with 0.3% low-melting temperature
agarose (Sigma-Aldrich) in phosphate-buffered saline and fixed with
4% paraformaldehyde in PBS before dehydration and paraffin embedding.
Sugen 5416–hypoxia rat model. Male Sprague Dawley rats (B150–200 g, Charles
River, Saffron Walden, Essex, UK) were administered a single subcutaneous
injection of Sugen 5416 (SU-5416; 20mg kg 1, Tocris, Bristol, UK) in vehicle
(0.5% carboxyl methylcellulose sodium, 0.4% polysorbate 80, 0.9% benzyl alcohol,
all Sigma-Aldrich). Subsequently, rats were placed into a 10% O2 chamber
for 3 weeks. After 3 weeks of hypoxia, animals were returned to a normoxic
environment for 5 weeks. At 8 weeks, rats were randomized into two groups. One
group received i.p. injections of 2.5mg kg 1 Etanercept (Enbrel Pfizer, Sandwich,
Kent, UK) diluted in Dulbecco’s phosphate-buffered saline (D8537, Sigma-Aldrich)
and the second group received vehicle alone. For terminal hemodynamic
measurements, rats were anesthetized with xylazine (4.6mg kg 1) and ketamine
(7mg kg 1). Body weight was recorded. Right and left ventricular function were
assessed using a Millar SPR-869 pressure-volume catheter. Tissue collecting
and assessment of right ventricular hypertrophy were conducted as described
above for mice.
Assessment of pulmonary vascular muscularization in mouse and rat tissues.
Paraffin-embedded mouse or rat lung tissue sections (5 mm thick) were incubated
with monoclonal mouse-anti-mouse/rat/human smooth muscle a-actin
(cat.no. M0851 clone 1A4, Dako; 1:400 dilution). In mouse lung, the primary
antibody was detected using the Dako ARK kit (Dako), in accordance with the
manufacturer’s instructions. Briefly, the primary smooth muscle a-actin antibody
was labelled with a biotinylated anti-mouse and then applied to the specimen.
A blocking agent, containing mouse serum, was then added to bind residual
biotinylation reagent not bound to primary antibody. The biotin-labelled
primary antibody was applied to the tissues sections, followed by incubation with
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streptavidin-peroxidase. Reaction with diaminobenzidine (DAB)–hydrogen
peroxide revealed the cellular location of immunostaining.
Pulmonary arteriolar muscularization was quantified by identifying small
pulmonary arteries adjacent to alveolar ducts. Arteries were classified by a blinded
observer as non-muscularized, partially muscularized, or fully muscularized,
following immunostaining for smooth muscle a-actin. A minimum of 20 vessels
(25–75 mm in diameter) were counted from each animal. Statistical significance was
determined by comparing the percentage of muscularized vessels between groups.
Percentage wall thickness of muscular small arteries (o100mm diameter)
was quantified in small arteries accompanying terminal bronchioles. Image J was
used to measure the diameter of the artery and the thickness of the medial layer
following immunostaining for smooth muscle a-actin. To determine wall thickness
four measurements were made, one in each quadrant of the artery. A minimum
of 10 arteries was measured in each lung section. Percentage wall thickness was
calculated as mean wall thickness divided by mean diameter x100. Morphometric
measurements were performed in a blinded manner by a single observer,
unaware of the experimental groups of the samples.
NOTCH2 and NOTCH3 immunohistochemistry in lung tissues. NOTCH2 and
NOTCH3 localization and expression in human and rat lung sections was
performed by staining fixed tissue sections using rabbit anti-NOTCH2
(cat #ab118824, Abcam, UK; 1:200 dilution) or rabbit anti-NOTCH3
(cat #5276; D11B8, Cell Signaling Technology; 1:800 dilution) and labelled
using immunoperoxidase (Vectastain Elite, Vector Laboratories, Peterborough,
Cambridgeshire, UK) and 3,30-DAB to create a brown coloured reaction product.
TNFa immunofluorescent staining in human lung tissue. For TNFa immu-
nostaining63, formalin-fixed paraffin-embedded sections of human lung tissue were
subjected to heat mediated antigen retrieval using citrate buffer, pH 6.0 and
incubated at 4 C overnight with 1:50 dilution in blocking buffer of rabbit
polyclonal anti-TNFa (IgG; cat no: ab8871 Abcam) and 1:250 dilution of mouse
monoclonal anti-human Smooth Muscle Actin (IgG2a, clone: 1A4; cat no: M0851,
Dako). After 5min ( 3) washes, sections were further incubated for 1 h at room
temperature with 1:100 dilution of secondary antibody in blocking buffer; donkey
anti-rabbit Northern Lights IgG-NL493 and donkey anti-mouse-Northern Lights
anti-mouse IgG-NL557 (R&D Systems) containing 1 mgml 1 Hoechst 33342
(cat no: H3570, Thermo Fisher, Loughborough, Leicestershire, UK). Sections
were mounted in Vectashield Mounting Media (Vector Laboratories) and
imaged with a Leica SPE confocal laser scanning microscope (Leica Microsystems
(UK) Ltd, Milton Keynes, UK). Controls included use of isotype-specific primary
antibody or non-immune serum.
Statistics. All data were analysed using GraphPad Prism and tested for normality
using a Kolmogorov-Smirnov test where numbers permitted. Data are presented
as mean±s.e.m. Data were analysed by one-way analysis of variance with
post hoc Tukey’s HSD analysis or paired two-tailed Student’s t-test where indicated.
Po0.05 was considered significant.
Data availability. The data that support the findings of this study are available
from the corresponding author on reasonable request.
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